Overview: Islet Cell Antibody Dilutions TestIntroduction: The Islet Cell Antibody Dilutions Test detects islet cell antibodies in dilutions to diagnose autoimmune diabetes, causing high blood sugar. Following 2023 ADA guidelines, it uses immunoassay with dilution techniques for high specificity, supporting diabetes screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected early or atypical type 1 diabetes.
Other Names: Islet Cell Ab Dil Assay, Autoimmune Diabetes Dilution Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Islet cell antibody dilution testing emerged in the 1980s with diabetes research. Advanced immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects islet cell antibodies in dilutions to diagnose autoimmune diabetes, guides treatment, and evaluates patients with high blood sugar.
Test Parameters: 1. Islet Cell Antibodies (Dilutions)
Pretest Condition: No fasting required. Collect serum or saliva. Report history of high blood sugar, fatigue, or diabetes symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document high blood sugar, fatigue, weight loss, or family history of diabetes. Include current medications, especially insulin.
Consent: Written consent required, detailing the tests purpose, diabetes implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay with dilution to detect islet cell antibodies in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for early autoimmune diabetes diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive islet cell antibodies in dilutions suggest early type 1 diabetes, guiding insulin therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: GAD65 antibodies, IA-2 antibodies, or C-peptide to confirm autoimmune diabetes diagnosis.
Test Limitations: Dilution increases specificity but may reduce sensitivity; clinical correlation is needed. Other autoimmune conditions may produce antibodies.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Atkinson MA, 2022.
